The invention relates to novel amidines and quanidines, the production and use thereof and the use thereof as trypsine-type serine protease competitive inhibitors, especially thrombine and compliment proteases CIs and C1r. The invention also relates to pharmaceutical compositions which contain said compounds as active ingredients, in addition to the use of the compounds as thrombine inhibitors, anticoagulants, compliment inhibitors and anti-inflammatory agents. The novel compositions are characterised by the linkage of a serine protease inhibitor having amidine or guanidine functions with an alkyl radical having two or more hydroxyl functions, whereby said alkyl radical is derived from sugar derivates. Several sugar structural components or components derived from sugar can therefore be linked to each other. Said principle of linking sugar derivates enables oral active compounds to be obtained.
本发明涉及新型的酰胺和
脲类化合物,其生产和使用以及作为胰
蛋白酶型
丝氨酸蛋白酶竞争性
抑制剂的用途,特别是作为凝血酶和补体
蛋白酶CIs和C1r的
抑制剂。本发明还涉及含有该化合物作为活性成分的制药组合物,以及将该化合物用作凝血酶
抑制剂、抗凝剂、补体
抑制剂和抗炎药的用途。这些新型化合物的特点是将具有酰胺或
脲基功能的
丝氨酸蛋白酶抑制剂与具有两个或更多羟基功能的烷基基团连接起来,其中该烷基基团来源于糖衍
生物。因此,几种糖结构组分或从糖中衍生的组分可以相互连接。该连接糖衍
生物的原理使得可以获得口服活性化合物。